Jentink et al. 2244 VPA 13 13 (Odds 0 – monotherapy Ratio, OR EUROCAT 5.2) case-control study Gilboa et al. – Meta-analysis - OR 5.8 Not stated meta-analysis of articles quoting association of VPA with birth defects 11 included Vajda et al. 447 VPA 5 No No exposed (mono distinction distinction or polytherapy) Endo et al. 25 VPA 1 0 1* polytherapy Moore et al. 34 VPA 0 0 0 monotherapy Kozma et al. – 70 VPA 3 3 0 monotherapy Samren et al. 184 VPA 0 0 0 monotherapy 118 VPA 1 No No polytherapy distinction distinction 323 VPA 3 2 1 et al.4 monotherapy *** NOTE: *In this case, the mother was taking 1400mg VPA, 1.5mg clonazepam and 200mg zonisamide daily. **2 of these cases (Winter et al and Okada et al.) were reported above as case reports
Jentink et al. – EUROCAT case-control study 2244 VPA monotherapy 13 13 (Odds Ratio, OR 5.2) 0 Gilboa et al. – meta-analysis Meta-analysis of articles quoting association of VPA with birth defects 11 included - OR 5.8 Not stated Vajda et al. 447 VPA exposed (mono or polytherapy) 5 No distinction No distinction Endo et al. 25 VPA polytherapy 1 0 1* Moore et al. 34 VPA monotherapy 0 0 0 Kozma et al. – 70 VPA monotherapy 3 3 0 Samren et al. 184 VPA monotherapy 0 0 0 118 VPA polytherapy 1 No distinction No distinction et al.4 *** 323 VPA monotherapy 3 2 1 NOTE: *In this case, the mother was taking 1400mg VPA, 1.5mg clonazepam and 200mg zonisamide daily. **2 of these cases (Winter et al and Okada et al.) were reported above as case reports
Accepted_Paper_Jackson_et_al_2016_Cleft_following_in_utero_exposure_to_valproate.docx